PhRMA joins Merck and BMS in suing over Medicare drug price negotiations
The pharma industry’s powerful lobbying group is suing the federal government after a stinging defeat on Capitol Hill last year and before CMS can begin implementing what PhRMA calls damaging drug price setting that could harm future innovation and patients.
Filed in district court in west Texas today, alongside the National Infusion Center Association and the Global Colon Cancer Association, PhRMA seeks to stop the enforcement of the price negotiations, which will begin in earnest this September, and the excise tax, which it says is unconstitutional.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.